ADVERTISEMENT
Videos
Analyzing the Financial Impact of Biosimilar Use in the Oncology Care Model for the US Oncology Network
07/12/2022
Puneeth Indurlal, MD, MS, The U.S. Oncology Network, McKesson, The Woodlands, TX, describes his study on the utilization and financial impact of biosimilar adoption in The Network during a performance period in the Oncology Care Model (OCM), a value-based care program from Medicare that rewards practices for decreasing the total cost of care.
Findings from this study suggest that the increased utilization of biosimilars in The Network resulted in significant savings in OCM.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Current Issue
June 2024
Volume 10
Issue 3
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Subscribe
Journal of Clinical Pathways Newsletter
Advertisement
Advertisement
Advertisement
Recent Stories
Advertisement